Merck (MRK) EVP Brian Foard submits initial insider Form 3

Rhea-AI Filing Summary

Merck & Co., Inc. executive Brian Foard, EVP, Specialty, Pharma, & ID, filed an initial statement of beneficial ownership on Form 3. The filing does not list any transactions or current holdings entries, serving mainly as a regulatory record of his status as a company officer.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Foard Brian

(Last) (First) (Middle)

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Specialty, Pharma, & ID

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Kelly E. Grez as Attorney-in-Fact for Brian Foard	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Merck (MRK) Form 3 filing for Brian Foard show?

The Form 3 for Brian Foard records his status as an officer of Merck & Co., Inc. It does not show any stock transactions or specific holdings, functioning primarily as an initial beneficial ownership registration with the SEC for this executive role.

Does the Merck (MRK) Form 3 for Brian Foard report any share purchases or sales?

No, the Form 3 reports no share purchases, sales, or other transactions for Brian Foard. All transaction-related counts, including buys, sells, exercises, gifts, and tax withholdings, are listed as zero in the filing’s summarized transaction data.

What is Brian Foard’s role at Merck (MRK) in this Form 3?

In this Form 3, Brian Foard is identified as an officer of Merck & Co., Inc. with the title “EVP, Specialty, Pharma, & ID.” The filing establishes his reporting status as a company insider for SEC disclosure purposes going forward.

Are any derivative securities reported for Brian Foard in the Merck (MRK) Form 3?

No derivative securities are reported for Brian Foard in this Form 3. The derivative summary section is empty, and derivativeTransactionCount and exerciseShares in the transaction summary are both zero, indicating no options or similar instruments are listed in this filing.

Does the Merck (MRK) Form 3 for Brian Foard indicate pre-planned trading or 10b5-1 plans?

The Form 3 does not indicate any pre-planned trading or Rule 10b5-1 plans for Brian Foard. Footnotes are present but do not add any transactional or trading-plan details, and the transaction counts in the summary all remain at zero.